QTP-101 is under clinical development by Quratis and currently in Phase II for Tuberculosis. According to GlobalData, Phase II drugs for Tuberculosis have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how QTP-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

QTP-101 overview

QTP-101 is under investigation for the prevention of tuberculosis. The vaccine candidate is a thermostable lyophilized formulation that comprises of multiple-antigen protein fusion vaccine composed of three virulent antigens (Rv3619, Rv3620, Rv2608) and one latency-associated antigen (Rv1813) with GLA-SE (TLR4 agonist)-based adjuvant.

For a complete picture of QTP-101’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.